California-based late-stage biotech company Alume Biosciences announced on Friday that it has named Rick Gonzalez as its new chief commercial officer.
Gonzalez has more than three decades of experience in the pharmaceutical industry, serving in senior roles that involved significant global responsibilities. He led the development and implementation of globalisation and commercialisation strategies across Europe, Asia, the Middle East and Latin America at Spectrum Pharmaceuticals. He has expertise in specialty markets including Surgery, HIV/AIDS, Hematology and Oncology, with a comprehensive background in sales, marketing, operations, distribution, managed markets and government affairs. Gonzalez has also worked in key roles at companies such as Abraxis Oncology, Genzyme, Ligand Pharmaceuticals, Roche Laboratories and GlaxoSmithKline.
Dr Quyen Nguyen, Alume Biosciences CEO, said: "Alume is thrilled to welcome Rick Gonzalez as our new chief commercial officer. Rick's profound global commercial, operational and leadership experience, particularly in surgery, biotechnology, radiopharmaceuticals and medical devices, is directly aligned with our strategic objectives. His proven track record in product commercialisation will be instrumental as we advance ALM-488 towards a successful market introduction."
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director